Aspire Biopharma (NASDAQ:ASBP) Releases Earnings Results

Aspire Biopharma (NASDAQ:ASBP) posted its quarterly earnings data on Thursday. The company reported ($1.22) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.06 million for the quarter.

Aspire Biopharma Stock Performance

Shares of NASDAQ:ASBP traded up $0.74 during midday trading on Friday, reaching $7.85. The company had a trading volume of 34,726 shares, compared to its average volume of 44,435. Aspire Biopharma has a 1-year low of $3.31 and a 1-year high of $1,050.36. The firm has a market cap of $10.21 million, a price-to-earnings ratio of -0.07 and a beta of 0.11. The company has a fifty day simple moving average of $6.50 and a two-hundred day simple moving average of $18.87.

Institutional Trading of Aspire Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of ASBP. Jane Street Group LLC boosted its holdings in shares of Aspire Biopharma by 2,252.1% in the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock worth $91,000 after buying an additional 658,886 shares during the period. XTX Topco Ltd increased its position in shares of Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after acquiring an additional 237,620 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Aspire Biopharma during the third quarter valued at approximately $28,000. Institutional investors and hedge funds own 19.17% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.